4/3
04:05 pm
tndm
Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025
Medium
Report
Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025
3/28
08:13 pm
tndm
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Medium
Report
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
3/26
10:16 am
tndm
3 Reasons to Sell TNDM and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Sell TNDM and 1 Stock to Buy Instead [Yahoo! Finance]
3/19
08:07 pm
tndm
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology [Yahoo! Finance]
Low
Report
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology [Yahoo! Finance]
3/19
10:00 am
tndm
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes
Medium
Report
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes
3/18
04:05 pm
tndm
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States
Low
Report
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States
3/18
09:50 am
tndm
3 Healthcare Stocks Walking a Fine Line [Yahoo! Finance]
Low
Report
3 Healthcare Stocks Walking a Fine Line [Yahoo! Finance]
3/5
08:08 am
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $22.00 price target on the stock, down previously from $45.00.
Low
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $22.00 price target on the stock, down previously from $45.00.
3/4
08:01 am
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $24.00 price target on the stock, down previously from $35.00.
Medium
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $24.00 price target on the stock, down previously from $35.00.
3/3
10:26 am
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $42.00 to $24.00. They now have a "neutral" rating on the stock.
Low
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $42.00 to $24.00. They now have a "neutral" rating on the stock.
3/3
08:10 am
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $22.00 price target on the stock, down previously from $38.00.
Medium
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $22.00 price target on the stock, down previously from $38.00.
2/28
05:09 pm
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at Barclays PLC from $60.00 to $53.00. They now have an "overweight" rating on the stock.
Medium
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at Barclays PLC from $60.00 to $53.00. They now have an "overweight" rating on the stock.
2/28
04:41 pm
tndm
FDA Roundup: February 28, 2025 [Yahoo! Finance]
Medium
Report
FDA Roundup: February 28, 2025 [Yahoo! Finance]
2/28
09:06 am
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $25.00 price target on the stock, down previously from $35.00.
Low
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $25.00 price target on the stock, down previously from $35.00.
2/27
07:08 pm
tndm
Tandem's insulin pump tech wins FDA nod for Type 2 diabetes [Yahoo! Finance]
Low
Report
Tandem's insulin pump tech wins FDA nod for Type 2 diabetes [Yahoo! Finance]
2/27
12:38 pm
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at Royal Bank of Canada from $65.00 to $55.00. They now have an "outperform" rating on the stock.
Low
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at Royal Bank of Canada from $65.00 to $55.00. They now have an "outperform" rating on the stock.
2/27
08:08 am
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at Robert W. Baird from $37.00 to $33.00. They now have a "neutral" rating on the stock.
High
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target lowered by analysts at Robert W. Baird from $37.00 to $33.00. They now have a "neutral" rating on the stock.
2/26
04:45 pm
tndm
Tandem Diabetes's (NASDAQ:TNDM) Q4 Sales Beat Estimates But Stock Drops 12.2% [Yahoo! Finance]
High
Report
Tandem Diabetes's (NASDAQ:TNDM) Q4 Sales Beat Estimates But Stock Drops 12.2% [Yahoo! Finance]
2/26
04:36 pm
tndm
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance [Yahoo! Finance]
High
Report
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance [Yahoo! Finance]
2/26
04:05 pm
tndm
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance
High
Report
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance
2/26
01:31 pm
tndm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $63.00 price target on the stock.
Low
Report
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $63.00 price target on the stock.
2/25
09:08 am
tndm
Tandem Diabetes Care gets FDA Clearance for its insulin delivery technology in Type 2 Diabetes patients [Seeking Alpha]
Low
Report
Tandem Diabetes Care gets FDA Clearance for its insulin delivery technology in Type 2 Diabetes patients [Seeking Alpha]
2/25
08:53 am
tndm
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes [Yahoo! Finance]
Low
Report
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes [Yahoo! Finance]
2/25
08:30 am
tndm
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes
Low
Report
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes
2/13
04:05 pm
tndm
Tandem Diabetes Care Announces Upcoming Conference Presentations
Low
Report
Tandem Diabetes Care Announces Upcoming Conference Presentations